LENSAR, Inc.

NASDAQ:LNSR

Medical - Devices

Healthcare
$4.85 -8.15%

-$0.51 today

Market cap
$59.63M
Beta
0.87
P/E (TTM)
2.4
EPS (TTM)
$2.42
52W Low $5.06High $13.47

Volume 0.06M

Average 0.09M

LNSR Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

LENSAR, Inc.NASDAQ: LNSR

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns negative

Q1 FY2026 accounts payables was -$3.89M, compared with $1.76M a year earlier. Trailing-twelve-month accounts payables was $7.34M. Over 3 fiscal years it compounded at +68.2% a year.

Context

  • Accounts payables amounted to 22.2% of revenue in FY2025, up 18.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$3.89M or moves back toward the trailing-twelve-month quarterly average of $1.84M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.89M-192.8% QoQ
Last fiscal yearDec 2025
$12.99M+564.0% YoY
LTMMar 2026
$7.34M+97.9% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-321.0%——
1 year+564.0%——
3-year CAGR+68.2%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
12.99M USD
Year-over-year change
+564.0%
4-year CAGR
+179.4%

Accounts Payables vs competitors

How LNSR compares with its peers on the latest reported figures

  • LNSR's LTM Mar 2026 accounts payables of $7.34M is the largest of the 10 companies compared; the peer median is $887K.
  • Its year-over-year change of +97.9% is the 4th highest of 10, against a peer median of +38.0%.
  • Accounts payables amounts to 12.7% of revenue for LNSR, versus a peer median of 5.4%.
LNSR Competitors Peer median
Accounts Payables for LNSR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LNSRLENSAR, Inc.LTM Mar 2026$7.34M +97.9%+68.2%12.7%
CRDFCardiff Oncology, Inc.LTM Mar 2026$5.21M +1496.2%+17.8%992.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$3.53M -272.3%+109.1%—
TLSITriSalus Life Sciences, Inc.LTM Mar 2026$2.37M +45.7%-27.2%5.3%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$2.03M +38.0%+2.5%5.9%
MXCTMaxCyte, Inc.LTM Mar 2026$1.77M -57.7%+191.8%5.5%
OWLTOwlet, Inc.LTM Mar 2026$951K -76.2%—0.9%
AVRAnteris Technologies Global Corp.LTM Mar 2026$887K +2749.0%—47.9%
ANIKAnika Therapeutics, Inc.LTM Mar 2026$740K +125.9%-72.2%0.6%
PROFProfound Medical Corp.LTM Mar 2026$387.3K -77.1%—2.1%
Peer median (excluding LNSR) $887K+38.0%+10.2%5.4%

Competitors are the stored peer set for LNSR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(19.6M)(19.91M)(14.38M)(31.4M)(34.28M)
Depreciation & Amortization2.76M3.41M3.52M3.93M4.5M
Deferred Income Tax527K0000
Stock-Based Compensation6.87M6.61M5.54M2.67M3.14M
Change in Working Capital(42K)(5.58M)(7.78M)(3.04M)1.1M
Accounts Receivables(2.65M)(1.44M)1.08M(2.1M)289K
Inventory2.33M(6.89M)(7.46M)(4.9M)(13.9M)
Accounts Payables213K2.73M(1.42M)1.96M12.99M
Other Working Capital66K23K23K2M1.72M
Other Non-Cash Items517K618K3.45M25.58M10.7M
Operating Cash Flow(8.97M)(14.86M)(9.66M)(2.28M)(14.83M)
Capital Expenditures(354K)(115K)(236K)(156K)(83K)
Acquisitions (Net)00000
Purchases of Investments00(3.92M)(10.25M)(11.88M)
Sales of Investments0008.24M13.25M
Other Investing Activities00000
Investing Cash Flow(354K)(115K)(4.16M)(2.16M)1.28M
Debt Repayment00000
Common Stock Issued361K408K058K258K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(2.4M)5.88M20K10M
Financing Cash Flow361K(1.99M)19.76M78K10.26M
Effect of Forex Changes00000
Net Change in Cash(8.96M)(16.96M)5.95M(4.36M)(3.29M)
Free Cash Flow(9.32M)(14.97M)(9.9M)(2.43M)(14.91M)

LENSAR, Inc.

NASDAQ:LNSR

Intrinsic Alpha fair value

Locked

Current Price

$4.85

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.